Enzymebiosystems (ENZB) 0.0150 $ENZB EnzymeBioSystems

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enzymebiosystems (ENZB) 0.0150 $ENZB

EnzymeBioSystems Product Development Update
PR Newswire - Thu Aug 20, 12:30PM CDT
EnzymeBioSystems (OTCBB: ENZB - News) announces that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the Company.

Amooranin completes preclinical sample batch of methyl amooranin for reduction of breast tumors
M2 - Tue Jul 28, 5:54AM CDT
Enzymes company EnzymeBioSystems (OTC BB:ENZB) reported on Monday that it has completed a preclinical methyl amooranin batch in the prevention of breast cancer.

Amooranin Preclinical Sample Batch Completed
PR Newswire - Mon Jul 27, 5:41PM CDT
EnzymeBioSystems (OTC BB: ENZB - News) announces that a preclinical methyl amooranin batch has been completed. Amooranin is the Company's lead pharmaceutical product. EnzymeBioSystems plans to seek approval for the use of methyl amooranin in the prevention of breast cancer.

Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS MCB).
AVXL: 3.70 (+0.68)

EnzymeBioSystems Cleared for OTCQB Listing
ACCESSWIRE - Mon Mar 16, 12:12PM CDT
LAS VEGAS, NV / ACCESSWIRE / March 16, 2015 / EnzymeBioSystems (OTCQB: ENZB) announced that it received notice of approval from OTC Markets Group, Inc. ("OTC Markets" that its stock will be listed on OTCQB Marketplace, effective March 16, 2015. ENZB submitted all the mandatory documents and has met all requirements for listing on the OTCQB Marketplace.

Market Maker Surveillance Report. NNBR, IDT, CTRV, ENZB, HTBX, ESCRP, Losing Stocks With Lowest Price Friction For Tuesday, March 10th 2015
M2 - Wed Mar 11, 4:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4960 companies with "abnormal" market making, 1371 companies with positive Friction Factors and 5291 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NN Inc (NASDAQ:NNBR), IDT Corp (NYSE:IDT), CARDILLO TRAVEL SYS (NASDAQ:CTRV), EnzymeBioSystems (OTC:ENZB), (NASDAQ:HTBX), (NASDAQ:ESCRP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
HTBX: 1.63 (-0.03), CTRV: 1.05 (+0.01), IDT: 14.21 (-0.43), ESCRP: 0.45 (+0.04), NNBR: 16.46 (-0.41)

EnzymeBioSystems' Amooranin preclinical sample batch to be completed by end of February 2015
M2 - Thu Feb 19, 5:13AM CST
Specialist enzymes company EnzymeBioSystems (OTCBB:ENZB) revealed on Wednesday that its preclinical methyl amooranin batch for the prevention of breast cancer nears completion.

Amooranin Preclinical Sample Batch Nears Completion
ACCESSWIRE - Wed Feb 11, 7:00AM CST
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.

Preclinical Xenograft Studies Show Positive Results For Amooranin
PR Newswire - Wed Dec 10, 12:45PM CST
EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.

EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid
PR Newswire - Mon Nov 17, 7:30AM CST
EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer. Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease. The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition). Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer. Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 23

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 11

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Charter Next Generation Unveils Gen 2 MDO-PE Films

Updated Category News Views 14

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Continue Reading
Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 13

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 28

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
NYSE Texas Redefines the U.S. Capital Markets Landscape

Updated Category News Views 21

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Continue Reading
Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

Updated Category News Views 21

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Continue Reading
Purina Institute Highlights Nutritional Science at WSAVA 2026

Updated Category News Views 19

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Continue Reading
IWP and VYRE Unveil 'The Plug' for VBNGtv Content

Updated Category News Views 20

Bringing Capital and Content Under One Roof There's something in the air as Itibari-Waynne & Partners (IWP) team up with the VYRE Network to crank out a fresh slate of content for VYRE Business News Global (VBNGtv). This partnership ain't just another splash in the buzzy world of digital media; it's like merging Wall Street with Hollywood. IWP, prepping to go full...

Continue Reading
Northern Jet Names Veteran Matthew Harris as CEO

Updated Category News Views 33

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Groundbreaking for New Community by Century Communities

Updated Category News Views 191

Century Communities Breaks Ground on New Development Century Communities, Inc. (NYSE: CCS) has recently made headlines with the groundbreaking of its newest venture: a magnificent 318-acre community named Mirabella. This family-friendly location promises to provide over 1,000 new homes designed for affordability and comfort. Situated within the bustling west metro area of...

Continue Reading
Perseus Group Enhances Manufacturing Software with OptiVision

Updated Category News Views 105

Perseus Group Strengthens Its Position in the Industry Perseus Group, a dynamic operating group within Constellation Software Inc., has taken a significant step in enhancing its offerings in the pulp and paper sector. They recently announced the completion of an exciting acquisition that will support their growth strategy. The group has secured the exclusive global...

Continue Reading
Embrace Pet Insurance Breaks Records in Volunteerism and Giving

Updated Category News Views 267

Embrace Pet Insurance Partners in Charity and Volunteerism Despite facing economic hurdles, charitable contributions across the nation showed remarkable resilience, highlighting the generosity of individuals and businesses alike. Recent reports reveal that charitable donations in the U.S. hit staggering heights, exceeding $557 billion in the last reporting year. Embrace...

Continue Reading
Biocon Biologics Achieves Key FDA Approval for Jobevne™ in Oncology

Updated Category News Views 173

Biocon Biologics Secures FDA Approval for Jobevne™ Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for Jobevne™ (bevacizumab-nwgd). This biosimilar to the well-known Avastin (bevacizumab) is designed for intravenous use and aims to treat various types of cancer....

Continue Reading